GLABF (Gemina Laboratories) Other Long-Term Liabilities: $0.00 Mil (As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Gemina Laboratories Other Long-Term Liabilities?

Gemina Laboratories GLABF -27.59% Other Long-Term Liabilities is $0.00 Mil as of Oct. 2025. The stock has 2 warning signs investors should review.

Gemina Laboratories's other long-term liabilities for the quarter that ended in Oct. 2025 was $0.00 Mil.

Gemina Laboratories's annual other long-term liabilities declined from Jan. 2023 ($0.00 Mil) to Jan. 2024 ($0.00 Mil) and declined from Jan. 2024 ($0.00 Mil) to Jan. 2025 ($-0.00 Mil).

Gemina Laboratories Other Long-Term Liabilities Related Terms

Gemina Laboratories Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Other Long-Term Liabilities Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Other Long-Term Liabilities
-0.00 0.00 0.00 0.00 -0.00

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00

Gemina Laboratories Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.00 Mil mean?
Gemina Laboratories (GLABF) has a Other Long-Term Liabilities of $0.00 Mil as of Oct. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Gemina Laboratories and its competitors.
Is Gemina Laboratories' Other Long-Term Liabilities too high?
Gemina Laboratories' current Other Long-Term Liabilities is $0.00 Mil.
How does Gemina Laboratories' Other Long-Term Liabilities compare to VRTX and REGN?
Gemina Laboratories' Other Long-Term Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Gemina Laboratories and its competitors. Gemina Laboratories's current Other Long-Term Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current Other Long-Term Liabilities of $0.00 Mil. The current Other Long-Term Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Other Long-Term Liabilities is $0.00 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.